A Pilot Study to Investigate the Efficacy of Partially Absorbable Mesh in Patients With Pelvic Organ Prolapsed

Patients with pelvic organ prolapse are administrated partially absorbable mesh(Seratom®PA). It is performed pelvic organ prolapse quantification(POP-Q) examination, quality of life(QOL) questionnaire complications at postop 2week, 12week, 24week.

Inclusion criteria

• Woman who aged 41 years or older
• Subjects who have symptomatic pelvic organ prolapse quantification(POP-Q) stage II & cystocele or higher requiring surgical repair
• Subjects who desires vaginal reconstructive surgery
• Subjects who have uterus < 12 weeks size
• Subjects who are able to complete study questionnaires and assessment
• Subjects who are available for 6 months follow-up

Exclusion criteria

• Subjects who have medical contractions, e.g. current urinary tract, vaginal or pelvic infection, history of pelvic irradiation, history of lower urinary tract malignancy, chronic steroid use, or a compromised immune system
• Subjects who have received anticoagulation therapy
• Subjects who are on current intermittent catheterization
• Subjects whose BMI is over 30kg/m2
• Subjects who have uncontrolled diabetes
• Subjects who are on any medication which could result in compromised immune response, such as immune modulators
• Subjects who are currently pregnant or intends to become pregnant during the study period or <12 months post-partum
• Subjects who have received other laparoscopic or abdominal or pelvic surgery in the past 1 months
• Subjects who need for concomitant surgery requiring an abdominal incision
• Subjects who have had a prior prolapse implant procedure (i.e. IVS tunneler, Perigee, Apogee, graft augmented repair, etc)

• Note: previous traditional repairs are allowed.
• Subjects who have had radiation therapy to the pelvic area
• Subjects who have pelvic cancer or have had pelvic cancer within the past 12 months or have had on cytostatic medication within the past 12 months
• Subjects who have a shortened vagina or other known Mullerian anomaly (e.g. uterine didelphys.)
• Subjects who have a known neurologic or medical condition affecting bladder function (e.g. Multiple Sclerosis, spinal cord injury)
• Subjects who have a known hypersensitivity to the graft material(s)